Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Interventional × orantinib × Clear all

Phase

Status

Sponsor Class

NIH 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 843 Carboplatin 789 Paclitaxel 776 Gemcitabine 650 Cisplatin 626 Docetaxel 589 Bevacizumab 507 Pemetrexed 409 Cyclophosphamide 397 Nivolumab 394 Capecitabine 377 Fluorouracil 332 Dexamethasone 325 Rituximab 317 Oxaliplatin 283 Injections 279 atezolizumab 250 Trastuzumab 245 Leucovorin 229 Cetuximab 229 Irinotecan 216 Prednisone 212 130-nm albumin-bound paclitaxel 212 Doxorubicin 209 Ipilimumab 187 Lenalidomide 185 fludarabine 178 Fulvestrant 178 durvalumab 171 venetoclax 164

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01465464 2019-08-07

ORIENTAL

Taiho Pharmaceutical Co., Ltd.

Phase 3 Terminated

888 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡